CVS Earnings Date: Nov 4, 2026 (Estimated) — CVS Health Corp.
NYSE · Healthcare · Healthcare Plans
Updated
When is CVS's next earnings date?
CVS Health Corp. (CVS) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.65 on revenue of $104.72B.
How did CVS do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), CVS Health Corp. posted EPS of $2.58 versus the $1.85 estimate, a beat of 40.2%. Revenue was $106.10B against a $100.03B estimate. The stock's 1-day post-earnings move was -5.1%.
How much does CVS stock move after earnings?
CVS beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.7% (up or down) in the day after earnings.
About CVS Health Corp.
CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | 1.85 | 2.58 | +40.22% | $106.10B | ✅ Beat | -5.08% | -10.46% | -6.89% |
| 2026-05-06 | Q1 2026 | 2.21 | 2.57 | +16.29% | $100.43B | ✅ Beat | +7.66% | +17.92% | +17.52% |
| 2026-02-10 | Q4 2025 | 0.99 | 1.09 | +10.10% | $105.69B | ✅ Beat | -0.09% | +3.20% | -0.07% |
| 2025-10-29 | Q3 2025 | 1.36 | 1.60 | +17.65% | $102.87B | ✅ Beat | -1.94% | -5.00% | -2.84% |
| 2025-07-31 | Q2 2025 | 1.47 | 1.81 | +23.13% | $98.90B | ✅ Beat | -0.31% | +1.97% | +15.80% |
| 2025-05-01 | Q1 2025 | 1.70 | 2.25 | +32.35% | $94.59B | ✅ Beat | +4.11% | +0.11% | -4.00% |
| 2025-02-12 | Q4 2024 | 0.93 | 1.19 | +27.55% | $97.71B | ✅ Beat | +14.96% | +20.73% | +19.56% |
| 2024-11-06 | Q3 2024 | 1.53 | 1.09 | -28.76% | $95.43B | ❌ Miss | +11.32% | -2.37% | +2.74% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $102.39B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Pharmacy Revenue | 59.4% | $60.83B | +9.9% | $56.24B | $52.51B | $55.35B | $59.55B |
| Premiums | 34.3% | $35.12B | +2.7% | $30.91B | $32.82B | $34.20B | $33.72B |
| Front Store Revenue | 5.3% | $5.41B | +0.7% | $5.67B | $5.24B | $5.37B | $5.19B |
| Product and Service, Other | 1.0% | $1.04B | -70.5% | $4.13B | $3.50B | $3.52B | $1.02B |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.